Baseline characteristics of patients with moderate‐to‐severe psoriasis according to previous systemic treatment exposure: the PROSE study population

Abstract

Introduction Psoriatic disease is associated with considerable impairment of Quality of Life (QoL). The PROSE study (NCT02752776) examined the impact of secukinumab on patient‐reported outcomes in patients with moderate‐to‐severe psoriasis (PsO) stratified by previous exposure to systemic treatment. Methods In this prospective, non‐randomised, multicentre study, patients were categorised at baseline according to previous exposure to systemic treatment: naïve (naïve to any systemic treatment [N=663]), conventional systemic (previously exposed to ≥1 conventional systemic therapy [N=673]), and biologics (previously exposed to ≥1 biologic [N=324]). Baseline demographics including age, gender, race, body weight and body mass index, disease characteristics and patient reported QoL outcomes (Dermatology Life Quality Index [DLQI], Family DLQI [F‐DLQI]) of patients enrolled in the study are reported here. Results Baseline demographic characteristics were well balanced across the three subpopulations. Naïve patients had a shorter time since diagnosis (15.5±12.1 years) compared with the conventional systemic (19.1±12.5 years) and biologic patients (23.0±12.5 years), and lower rates of psoriatic arthritis (6.6% versus 17.4% and 27.8%, respectively). Metabolic syndrome (37.6‒43.5%), obesity (16.9‒19.1%), hyperlipidemia (15.3‒21.9%) and diabetes mellitus (6.8‒14.2%) were reported at numerically higher rate in the biologic group. The mean PASI (19.7±7.9), affected Body Surface Area (28.2±15.3%) as well as the Investigator Global Assessment score (patients with score 4: 33.7%) indicated severe disease at baseline and were comparable for the three groups. QoL impairment was evident from mean DLQI (14.1±7.1: naïve=13.5±6.8; conventional systemic=14.3±7.0; biologic=14.8±7.7) and mean F‐DLQI (11.5±7.0: naïve=11.3±7.1; conventional systemic=11.4±6.7; biologic=12.1±7.7) also indicated derangement of QoL of patients and their families. Conclusion Patients naïve to systemic treatment had shorter disease journey compared with patients previously exposed to systemic treatments; despite this, the severe impact of disease on patient and family QoL outcomes can be as apparent in naïve patients as in systemically‐treated patients at baseline.